MedTrace Logo

Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)

NCT00070707 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2024-09-05

Study results available
· View outcomes & findings →

Summary

This study will compare mometasone nasal spray to placebo in treating the nasal and asthma symptoms experienced by participants with seasonal allergic rhinitis (SAR) and concomitant asthma.

Conditions

  • Rhinitis, Allergic, Seasonal
  • Asthma

Interventions

DRUG

Mometasone

Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.

DRUG

Placebo

Matching placebo nasal spray, administered QD as 2 sprays in each nostril.

DRUG

Albuterol/Salbutamol

Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.

Sponsors & Collaborators

  • Integrated Therapeutics Group

    collaborator INDUSTRY

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medial Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-03
Primary Completion
2003-11-26
Completion
2003-11-26
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00070707 on ClinicalTrials.gov